How to Read a Supplement COA—and What “Third-Party Tested” Means

Pure City Editorial
Last reviewed: 31 August 2026

Quick answer: how do you read a supplement COA?

A Certificate of Analysis (COA) records tests or examinations for a named material or product lot. It may come from a supplier or an outside laboratory, so do not assume it is independent. Check the product and lot identity, sample stage, test method, specification or limit, actual result, testing organization and dates. No finished-lot COA is currently available for the four pre-order products.

A useful COA connects one identifiable sample to one set of methods, limits and results. A polished PDF without that chain can look reassuring while answering the wrong question. First separate the retail label from the test report. Then ask: can you tell what was sampled, which lot it came from, what was tested, how it was tested, what limit applied, what the laboratory found and who approved the report?

This guide explains how to make that check. It does not rate a supplement’s clinical effectiveness and does not turn a pending specification into a finished-product fact.

COA vs specification vs certificate of conformance

These documents answer different questions.

Document Main question What useful evidence looks like What it cannot establish by itself
Specification What must this material or product meet? Named tests or attributes, acceptance criteria, units and the applicable version Whether a particular lot was tested or passed
Certificate of Analysis What was examined or tested for this named lot, and what was found? Lot identity, sample stage, method, limit, actual result, dates and testing organization Independence, correct sampling, clinical benefit or every unlisted quality attribute
Certificate of Conformance or Conformity Does the issuer attest that the lot conforms to an agreed requirement? The product and lot, referenced standard or specification, issuer and authorization The underlying numerical results unless they are also supplied

A supplier COA is not automatically a third-party COA. In United States dietary-supplement manufacturing rules, a manufacturer may rely on a supplier’s certificate for certain component specifications only after qualifying the supplier and confirming the certificate’s reliability. The certificate must include the test or examination methods, limits and actual results. That is a control process—not a reason to treat every supplier document as independent proof.

Supplement Facts vs a COA: what each can—and cannot—prove

Quick answer: A US Supplement Facts panel declares what the seller represents one serving to contain. A specification sets the criteria a product is expected to meet. A COA reports selected results for an identified sample or lot. None is a clinical trial. Read the label for serving size and declared ingredients, connect a finished-lot report to the product and lot you would receive, then evaluate human evidence for the exact form, amount, population and outcome being discussed.

A label is a declaration; a COA is a result for a named sample

The FDA’s general dietary-supplement labeling guide identifies five core US label statements: the product identity, net quantity, nutrition labeling, ingredient list, and name and place of business of the manufacturer, packer or distributor. The Supplement Facts panel normally adds the serving size, servings per container, dietary ingredients and their quantities.

Those declarations are useful, but the label is not a laboratory report. FDA generally does not approve a dietary supplement or its labeling before sale. A label cannot by itself establish that an outside laboratory tested the customer’s lot, that every capsule contains the declared amount, that contaminants met appropriate limits, or that the product works for a health outcome.

Layer What it can tell you What it cannot establish by itself
Supplement Facts and the rest of the retail label Serving basis, declared dietary ingredients and amounts, Other Ingredients, net contents, business identity, directions and displayed claims Actual results for the customer’s lot, independent testing, complete contaminants, clinical effectiveness or personal suitability
Specification The identity, strength, activity, contaminant or other acceptance criteria that should be met That a sample was tested or passed
Finished-lot COA or test report Methods, limits and reported results for an identified finished-product sample or batch, if authentic and correctly linked Every risk not tested, clinical benefit, personal suitability, or that a raw-material result automatically covers the finished product

Check serving size before comparing the label with a result

Start at Serving Size, then read the heading over the quantities. Under 21 CFR 101.36, the panel can say Amount Per Serving, Each Tablet Contains, Amount Per 2 Tablets, or another clearly identified basis.

If the serving is two capsules and the panel declares 500 mg per serving, the label represents 500 mg across those two capsules—not 500 mg in each. A composite finished-product assay might estimate the average amount in a sampled set, but it does not automatically prove the content of each dosage unit. Ask what sample was used and whether an appropriate dosage-unit consistency or uniformity check was performed when that distinction matters.

Also keep units intact. mg, mcg and g measure mass. Do not compare values expressed in different units without a documented basis.

% Daily Value and proprietary blends answer narrow questions

The FDA’s Daily Value explainer describes % Daily Value as the contribution of one serving relative to an FDA Daily Value. It is not a personalized need, treatment target, upper limit, effectiveness score or purity result.

Daily Value not established means FDA has not established a Reference Daily Intake or Daily Reference Value for that dietary ingredient. It does not mean that the ingredient works, does not work, is safe, is unsafe, is unregulated or was tested.

For a proprietary blend, 21 CFR 101.36(c) requires the combined weight of the blend’s other dietary ingredients and lists them in descending order of predominance. Their individual amounts need not be disclosed. The practical limitation is dose transparency: you cannot reliably compare an undisclosed individual amount with a study or another formula. The format alone is not proof of illegality, deception, ineffectiveness or harm.

Ingredients outside the Supplement Facts panel appear in an ingredient list. FDA explains that the heading is Other Ingredients when some source ingredients are identified within the panel, and gives examples including binders, colors, excipients, fillers, flavors and sweeteners. Their presence alone is not a quality verdict; check their actual function and relevance to allergies, dietary restrictions or preferences.

Use three proof layers—not one reassuring document

  1. Label layer — what is represented? Record the serving size, exact ingredient name and form, declared amount and unit, Other Ingredients, claims and directions. Do not detach a number from its serving basis or source form.
  2. Lot layer — what was actually reported? Match the finished product and lot, then check sample stage, method, specification, actual result, dates, testing organization and any claimed laboratory scope. A supplier or raw-material COA does not automatically verify the finished bottle.
  3. Clinical-evidence layer — what outcome is supported? Compare the actual form, delivery, amount, population, duration and outcome with the relevant human evidence. Correct identity and label strength are product facts; they do not turn a supplement into a proven treatment.

Pure City status — 31 August 2026: No final commercial label or finished-lot COA is currently published for the four listed pre-order products. Current forms and amounts are presented as planned specifications, not verified finished-lot results. Compare the current pre-order specifications and release status.

The nine fields to check

1. Product or material name

The report should identify the material clearly enough to connect it to the ingredient or finished product. A generic heading such as “CoQ10” is weaker than a name that distinguishes the ingredient form and sample stage.

2. Lot or batch number

The lot on the report should match the lot being evaluated. A “typical,” “sample” or undated report may illustrate a format, but it does not show what happened to the lot offered for sale.

3. Sample stage

Look for whether the sample was a raw ingredient, an in-process blend, a bulk tablet or capsule, or the finished packaged product. Results from one stage must not be silently presented as proof about another.

4. Sample and report dates

The collection, receipt, test and approval dates help establish sequence. A report created before the relevant lot existed cannot be its finished-lot COA.

5. Test or analyte

The report should name what was examined: identity, assay or strength, a particular contaminant, microbiological measure, physical attribute or another product-specific requirement. “Purity tested” is not a test name.

6. Method

The method may be a recognized compendial method, a validated internal method or another scientifically valid examination. The report should identify it well enough for a qualified reviewer to understand what produced the result. A method suited to identity does not automatically measure quantity, and a quantitative assay does not reconstruct manufacturing history.

7. Specification, limit and units

The acceptance criterion belongs beside the result. “0.8” means little without its unit and the limit it is being compared with. The relevant limits depend on the product, market, method and risk; there is no single universal supplement panel or universal limit table that this page can responsibly substitute.

8. Actual result

Prefer the measured value when the method produces one. “Pass” alone is not always wrong—a qualitative identity examination may appropriately report a match—but the report should still identify the method and acceptance criterion. A numerical test should not be reduced to “complies” when the actual result is needed to understand the finding.

9. Testing organization and authorization

The report should identify who performed or took responsibility for the work, with a report identifier and approval where applicable. If laboratory accreditation is cited, check the issuing accreditation body, certificate status and scope rather than relying on a logo.

Raw-material COA vs finished-product COA

A raw-material COA can be important evidence about an incoming ingredient. It cannot, by itself, establish what is true after manufacturing.

The finished product may add other ingredients, introduce new process risks or distribute the active unevenly across dosage units. A raw-material assay does not prove the amount in each finished capsule or tablet. A raw-material contaminant result does not automatically cover contaminants or microbiological conditions relevant after production and packaging. A supplier document also does not prove that the tested input is the same lot used in the finished product unless traceability records connect them.

Finished-product evidence should be selected for the product and its risks. That does not mean every lot needs an invented one-size-fits-all panel. It means the manufacturer must define appropriate specifications and have a defensible basis for the tests, examinations, process controls and sampling used to show that the finished batch meets them.

Identity, strength, composition and contaminants

United States dietary-supplement current good manufacturing practice rules provide a useful vocabulary for this distinction. They require product specifications for identity, purity, strength and composition, along with limits on types of contamination that may adulterate or lead to adulteration of the finished batch. They also require appropriate, scientifically valid tests or examinations and documented reasoning for the selected finished-batch verification.

Those rules are manufacturing requirements in a particular jurisdiction. They do not mean that FDA pre-approves a dietary supplement or tests it before sale. A brand should not turn “manufactured under dietary-supplement CGMP requirements” into “FDA approved,” and a consumer should not treat an FDA disclaimer as a substitute for evaluating the actual evidence.

What “third-party tested” does—and does not—mean

“Third-party tested” should answer who performed the test and how that organization relates to the brand, manufacturer and supplier. It should not function as a decorative synonym for “quality.”

Ask:

  • Who selected the sample?
  • Was the sample drawn from the actual saleable lot?
  • Who paid for the work?
  • Who performed each test?
  • Is that laboratory legally and operationally separate from the brand and manufacturer?
  • Which method and analyte were used?
  • Was that work within the laboratory’s accredited scope?
  • Can the report be matched to the product lot received by the buyer?

Paying an outside laboratory is normal and does not, by itself, invalidate the work. Independence is about control, sample custody, competence, method, reporting and the ability to audit the chain—not whether money changed hands.

ISO/IEC 17025 sets general requirements for the competence, impartiality and consistent operation of testing and calibration laboratories. An accreditation reference is useful only in context. It does not prove that the laboratory tested the right sample, that every method it offers is accredited, that the brand selected the right analytes, or that the finished product meets an untested claim. Check the current accreditation scope for the relevant method or field of testing.

How to read “pass,” ND, LOD and LOQ

  • Pass or complies: the issuer says the result met an acceptance criterion. Look for the criterion, method and—when quantitative—the actual value.
  • ND or not detected: the analyte was not detected under the method’s reporting rules. It does not mean the amount is literally zero.
  • LOD or limit of detection: the method’s estimated or validated boundary for detecting that an analyte is present. The exact definition and calculation belong to the method.
  • LOQ or limit of quantitation: the boundary above which the analyte can be quantified with the method’s stated performance. It is generally higher than the detection limit.
  • Less than a value: the result is below the stated reporting or quantitation threshold. Keep the unit and threshold attached; “below limit” without them is incomplete.

Two reports can use different methods, limits and units. Do not compare isolated numbers until those differences are reconciled.

How to Read Heavy Metals on a Supplement COA

Direct answer: First match the report to the product, lot and sample stage. Then check the analyte or species, test method, result, unit, reporting limit and acceptance criterion. If a solid-product result is reported on a mass-per-mass basis, 1 ppm = 1 mg/kg = 1 µg/g. You can then calculate:

µg per serving = ppm × grams of the same tested material per serving

That calculation translates a concentration into the amount represented by a serving of the tested material. It does not choose a safety limit, show total exposure from food, water or other products, measure absorption, or prove compliance with a law or standard.

Start with the sample, not the number

Before calculating anything, ask:

  • What was tested? A raw ingredient, in-process blend, capsule contents, whole tablet, powder or another finished-product sample?
  • Which lot? Does the report identify the lot being evaluated?
  • Which analyte or species? Does it say lead, cadmium, mercury, total arsenic, inorganic arsenic or something else?
  • Which method and reporting convention? Are the method, result, unit, detection or quantitation threshold and any qualifier defined?
  • Which specification? Is the acceptance criterion named, with its source and version?

A raw-ingredient result cannot simply be multiplied by the finished serving size and presented as a finished-product result. Manufacturing adds other materials and changes the mass basis. The report, batch records and formula must establish what the tested concentration applies to.

Convert ppm to micrograms per serving only when the basis matches

For a solid sample reported as a mass fraction:

  • 1 ppm = 1 mg/kg
  • 1 mg/kg = 1 µg/g
  • therefore, µg per serving = ppm × grams of tested material in that serving

Hypothetical example—not a Pure City result: A finished-product homogenate is reported at 0.20 ppm for lead, and one serving contains 1.5 g of that same tested material.

0.20 µg/g × 1.5 g = 0.30 µg per serving

If the labelled maximum use were two servings per day, the product would represent 0.60 µg per labelled maximum day in this hypothetical. That is an arithmetic result for this one product and use assumption. It is not a total-exposure estimate and is not, by itself, a safety or compliance conclusion.

Use the mass of the same matrix the laboratory tested. The declared amount of one active ingredient is not automatically the serving mass. A capsule count is not a mass. If the report covers capsule contents rather than shells, the matching mass is the contents represented in a serving. If that mass or the test basis is unavailable, the conversion cannot be completed responsibly.

For a liquid or a result reported on a volume basis, do not automatically treat ppm as µg/g or assume mg/L can be converted without the report's basis and, when needed, density. Keep the laboratory's original unit and basis attached.

ND is not zero, and a reporting threshold is not a measured result

Laboratories may use ND, LOD, LOQ, reporting limit or another defined term differently. Read the report's qualifier key and method before interpreting it.

  • If a report says only ND, it does not provide a numerical zero or a usable upper bound.
  • If it says ND <0.05 ppm and defines 0.05 ppm as the applicable reporting threshold for the same finished solid matrix, a 1.5 g serving can be described as less than 0.075 µg per serving at that reporting threshold: 0.05 µg/g × 1.5 g = 0.075 µg. This is a converted reporting bound, not a measured amount and not zero.
  • A result below an LOQ may indicate that the analyte could not be quantified with the method's stated performance; some reports also distinguish detection below the LOQ. Use the laboratory's definition rather than assuming every <LOQ or ND means the same thing.
  • A lower reporting threshold can provide a tighter bound, but it does not prove that the sample was representative, the correct species was measured, or every unit in the lot has the same concentration.

Total arsenic is not inorganic arsenic

A row labelled only Arsenic (As) may report total arsenic. It does not, by itself, tell you how much was inorganic arsenic. FDA explains that inorganic arsenic is generally more toxic than organic forms and uses separate analytical work to distinguish species when needed. FDA's published methods likewise distinguish total-element analysis by ICP-MS from arsenic-speciation analysis by HPLC-ICP-MS.

Look for an explicitly named species or speciation method and result. Do not relabel a total-arsenic value as inorganic arsenic, and do not treat every organic arsenic form as harmless. If only total arsenic is reported, describe it as total arsenic and state that the species were not resolved by that result.

Three frameworks, three different questions

Framework Question it helps answer What it does not establish by itself
FDA dietary-supplement CGMP requirements Has the manufacturer established appropriate product specifications—including relevant contamination limits—and used scientifically valid tests or examinations and a documented verification approach for the finished batch? The CGMP provisions do not supply one universal heavy-metals concentration table for every supplement. CGMP is not FDA pre-approval, and a CGMP statement is not a lot result.
USP General Chapter <2232> Does a finished dietary-supplement dosage form labelled as conforming to USP or NF meet the elemental-contaminants chapter within its stated scope? The chapter is not another name for FDA CGMP. Its stated scope is finished dosage forms labelled to conform to USP or NF; it is not a universal claim about every supplement or a result for an untested lot. USP says dietary ingredients are addressed through their corresponding monographs rather than this finished-dosage-form scope.
California Proposition 65 Could an exposure to a listed chemical require a California warning under the law and its regulations, after applying the relevant exposure assumptions, coverage and exemptions? A concentration in ppm alone does not answer the exposure question. A Proposition 65 warning is not a government finding that a product is safe or unsafe, and meeting a federal composition or manufacturing requirement does not automatically resolve Proposition 65.

Do not compare a COA number with a copied internet limit until you know the jurisdiction, product category, chemical species, exposure or concentration basis, serving assumptions, applicable version, test method and who set the criterion. A laboratory's Pass statement answers only the named specification on that report.

What one COA still cannot tell you

Even a clear finished-lot result does not show that every dosage unit is identical. Sampling, homogenization, subsampling, method recovery, measurement uncertainty and lot traceability affect what the result represents. A composite result can estimate the tested composite; it does not reconstruct the value for every individual tablet or capsule.

It also cannot determine whether a supplement is appropriate for a particular person. Exposure and health questions can depend on the chemical form, amount, duration, other exposure sources, age, pregnancy, medical conditions and other factors. Ask an appropriately qualified professional about personal medical or legal decisions.

Pure City status

No finished Pure City production lot or finished-lot COA is public as of 31 August 2026. The numbers above are hypothetical teaching examples, not Pure City specifications, results or safety claims. Production, supplier verification and finished-lot evidence remain pending.

For the broader document check, read how to compare Supplement Facts with a COA and Pure City's planned sourcing requirements. Planned requirements must not be described as completed testing. For more product-quality explainers, browse Pure City's evidence and sourcing guides.

Sources and scope

This explanation uses United States and California examples. Requirements vary by product, chemical, market and date. It is educational material, not laboratory, regulatory, legal or medical advice.

COA red flags

Pause when a report has one or more of these problems:

  • The lot number is missing or does not match the product.
  • The document is labelled “typical,” “sample” or “reference” rather than belonging to the relevant lot.
  • It does not say whether the sample was a raw ingredient or finished product.
  • Methods, limits or units are missing.
  • Every quantitative result is reduced to “pass.”
  • The laboratory or testing organization is unnamed.
  • Pages, headers, approval fields or report identifiers appear cropped or edited.
  • An accreditation logo is shown without a verifiable certificate and relevant scope.
  • A raw-material result is presented as proof of finished dosage-unit strength.
  • One identity or assay result is used to imply manufacturing route, vegan status, clinical effectiveness or broad safety.

One red flag is not automatic proof of misconduct. It is a reason to ask for the missing chain rather than filling the gap with trust language.

What a COA cannot prove

Even a strong finished-lot COA has boundaries. By itself, it cannot prove:

  • that a supplement is clinically effective for a condition;
  • that it is appropriate or safe for a particular person;
  • that its ingredients have a particular manufacturing route unless the method and records can establish that route;
  • organic, vegan, halal, kosher, non-GMO or sustainability status without the relevant separate evidence;
  • bioavailability or equivalence to a formulation used in a human trial;
  • FDA approval;
  • stability through the expiry date without suitable stability evidence; or
  • that every quality risk was tested merely because the listed tests passed.

Quality evidence and health-outcome evidence are different layers. A correct identity and assay are necessary product facts; they do not turn the product into a treatment.

Pure City first-run status

As of 31 August 2026, production remains pending. No finished-lot COA is currently available for the four pre-order products. The product pages describe planned specifications; supplier documents and finished-lot results must not be described as completed facts.

Current planned specifications:

Review the current pre-order terms and current pre-order specifications and release status. Where a product-specific statement differs from this page, the narrower, newer and directly supported statement should control.

A 60-second buyer checklist

Ask these questions before treating a COA as evidence for the bottle or order in front of you:

  • Does the product or material name match?
  • Does the lot on the bottle or order match the report?
  • Does the report identify raw material, in-process material or finished product?
  • Are the sample, test and approval dates visible?
  • Is each test or analyte named?
  • Is the method identified?
  • Are the specification, limit and units shown?
  • Is the actual result supplied where the method is quantitative?
  • Is the laboratory or testing organization named, and is any claimed accreditation scope verifiable?
  • Can the brand explain what the COA does not prove?

If the chain breaks, ask for the missing evidence. Do not replace it with a badge, slogan or screenshot.

Sources, scope and last reviewed

This guide uses United States dietary-supplement manufacturing rules as one concrete regulatory example and ISO/IEC 17025 for laboratory competence context. Requirements vary by product and jurisdiction. It is educational material, not legal, regulatory, laboratory or medical advice.

Source independence note: eCFR reproduces current regulatory text; FDA explains its own regulatory framework; ISO publishes the standard it sells; and ILAC publishes accreditation guidance. These sources are authoritative for what their rules, standards and guidance say, but they do not audit Pure City, its suppliers or any future lot. No product-specific evidence is inferred from them.